GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » 3-Year EBITDA Growth Rate

XTL Biopharmaceuticals (XTAE:XTLB) 3-Year EBITDA Growth Rate : 10.60% (As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is XTL Biopharmaceuticals 3-Year EBITDA Growth Rate?

XTL Biopharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was ₪0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 10.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 3.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 17.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of XTL Biopharmaceuticals was 73.80% per year. The lowest was -110.80% per year. And the median was 19.40% per year.

Competitive Comparison of XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate falls into.


XTL Biopharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

XTL Biopharmaceuticals  (XTAE:XTLB) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

XTL Biopharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

XTL Biopharmaceuticals (XTAE:XTLB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (XTAE:XTLB) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
XTAE:CANF XTAE:PPBT XTAE:CBI XTAE:MTLF XTAE:KDST XTAE:BOLT XTAE:PLNT XTAE:HDST-M XTAE:DNA XTAE:GFC-M OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
XTLB:USA H2K2:Germany
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
Website
https://www.xtlbio.com
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.